| News
Biosynex takes up residence in Delémont
26.02.2021
The French company Biosynex develops analytical, diagnostic and prophylactic medical devices. Its portfolio includes a test for Covid-19. It has had a site in Delémont since the start of the year and plans to continue on its growth course from there.

Thierry Paper (Deputy Managing Director), Larry Abensur (CEO), Thomas Lamy (Deputy Managing Director)
Biosynex specializes in rapid tests and has launched numerous products for women over recent years, such as fertility tests and pregnancy tests. The French firm with headquarters in Illkirch-Graffenstaden in the Alsace region of France also launched a rapid test for Covid-19 last year, which is being manufactured in France. In order to respond to increasing demand from Switzerland, Biosynex has decided to set up a branch there and is now established in Delémont.
Back in 2018, Fribourg was the original destination for Biosynex’s Swiss branch. However, at the start of 2021, the move was made to Delémont and thus to the Basel Area. According to CEO Larry Abensur, firstly, the proximity to Alsace was one plus point for the location in Jura, but the favorable environment for companies in the life sciences sector in particular, with the “efficient laboratories, academic and private research centers” it provides, was another reason for the new location. In Delémont, Biosynex now not only has the desired infrastructure with offices and storage all in one building, it is also in a position to achieve its new growth targets from its location in Delémont. These have become significantly more ambitious since 2018.
The four acquisitions Biosynex has made over the past four years are testament to this. One such acquisition was of the American company ProciseDx, which develops products for gastroenterology (relating to disorders of the digestive system). Biosynex was founded in 2005 and currently employs over 200 members of staff. Its products are sold in 60 countries.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
KUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read More